Q1 2025 Earnings Call Transcript April 30, 2025 GeneDx Holdings Corp. beats earnings expectations. Reported EPS is $0.27, ...

GeneDx beat Wall Street's revenue and adjusted earnings expectations for the first quarter of 2025. Shares of GeneDx Holdings ...

Reported first quarter 2025 revenues of $87.1 million with 62% year-over-year growth of exome and genome test revenue.

GeneDx (WGS) stock plummets 41% despite reporting strong Q1 2025 results with a 42% revenue growth, improved margins, and ...

GeneDx Holdings is revolutionizing healthcare with genomic sequencing, AI, and expanded diagnostics. Learn more about WGS ...

Retail investor interest surged Wednesday around GeneDx Holdings Corp after the company’s shares plunged nearly 43% despite ...

GENEDX HOLDINGS (WGS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

GeneDx has announced its intention to acquire Fabric Genomics, a move that positions it to advance in the field of genomic ...

In its first-quarter 2025 investor letter, Alger Small Cap Focus Fund highlighted stocks such as GeneDx Holdings Corp.

People with diseases caused by rare mutations have fewer options and poorer prospects than other patients despite rapid ...

Combining GeneDx’s industry-leading rare disease data asset and Fabric Genomics’ AI-powered platform furthers the Company’s leadership and creates an unrivaled platform to deliver global ...